1. Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma
- Author
-
Goda Kalinauskaite, Stephanie E. Combs, Mechthild Krause, Fabian Lohaus, Maja Guberina, Andreas Schreiber, Annett Linge, Panagiotis Balermpas, Michael H. Baumann, Karoline Leger, Inge Tinhofer, Nika Guberina, Steffen Löck, Jan C. Peeken, Alex Zwanenburg, Daniel Zips, Jens Müller-von der Grün, S. Böke, Stefan Leger, Claus Belka, Asier Rabasco Meneghetti, Esther G.C. Troost, Ute Ganswindt, University of Zurich, and Löck, Steffen
- Subjects
medicine.medical_specialty ,Locally advanced ,Medizin ,R895-920 ,Biomarker ,Hnscc ,Loco-regional Control ,Machine Learning ,Radiomics ,Validation ,610 Medicine & health ,HNSCC ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Medical physics. Medical radiology. Nuclear medicine ,0302 clinical medicine ,regional control ,Machine learning ,medicine ,2741 Radiology, Nuclear Medicine and Imaging ,Radiology, Nuclear Medicine and imaging ,In patient ,ddc:610 ,RC254-282 ,business.industry ,Loco-regional control ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Head and neck squamous-cell carcinoma ,10044 Clinic for Radiation Oncology ,Confidence interval ,HNSCC Radiomics Validation Biomarker Machine learning Loco ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Biomarker (medicine) ,2730 Oncology ,Radiology ,business - Abstract
Purpose To develop and validate a CT-based radiomics signature for the prognosis of loco-regional tumour control (LRC) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated by primary radiochemotherapy (RCTx) based on retrospective data from 6 partner sites of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG). Material and methods Pre-treatment CT images of 318 patients with locally advanced HNSCC were collected. Four-hundred forty-six features were extracted from each primary tumour volume and then filtered through stability analysis and clustering. First, a baseline signature was developed from demographic and tumour-associated clinical parameters. This signature was then supplemented by CT imaging features. A final signature was derived using repeated 3-fold cross-validation on the discovery cohort. Performance in external validation was assessed by the concordance index (C-Index). Furthermore, calibration and patient stratification in groups with low and high risk for loco-regional recurrence were analysed. Results For the clinical baseline signature, only the primary tumour volume was selected. The final signature combined the tumour volume with two independent radiomics features. It achieved moderately good discriminatory performance (C-Index [95% confidence interval]: 0.66 [0.55–0.75]) on the validation cohort along with significant patient stratification (p = 0.005) and good calibration. Conclusion We identified and validated a clinical-radiomics signature for LRC of locally advanced HNSCC using a multi-centric retrospective dataset. Prospective validation will be performed on the primary cohort of the HNpradBio trial of the DKTK-ROG once follow-up is completed.
- Published
- 2021
- Full Text
- View/download PDF